Introduction
Tuberculosis meningitis (TBM), an extrapulmonary form of tuberculosis, has emerged as one of the most lethal types of disease, accounting for approximately 0.6–1.8% of tuberculosis cases with reported mortality rates of up to 30–50%.1 The TBM prognosis is often closely related to the severity of the disease, early therapeutic interventions, and the optimum concentration of drugs crossing the blood-brain barrier (BBB).2 Among various chemotherapeutics, isoniazid is considered an important drug against TBM due to its early antimicrobial effect and high permeability crossing BBB.
Currently, the World Health Organization (WHO) regimen has advised a quadruple therapeutic regimen for TBM consisting of isoniazid, rifampin, ethambutol, and pyrazinamide. The…